article thumbnail

Scandinavia: insight into opportunities for drug discovery

Drug Discovery World

DDW Editor Reece Armstrong explores the Scandinavian drug discovery sector and speaks to key players about Sweden’s place in the market. Scandinavia represents one of the most exciting but perhaps underrepresented markets for the discovery and development of pharmaceuticals. We have 3,000 companies in the life sciences sector.

article thumbnail

Gene editing: beyond the hype

pharmaphorum

Since Macrae joined the company just four years ago, Sangamo has more than tripled its staff and raised $1.6 It has also built its own manufacturing site and launched partnerships with six big pharma companies. Zinc fingers are the most common control gene in the body,” Macrae explains. “We billion in funding.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Fibrosis research: Advances and challenges 

Drug Discovery World

Wigerinck has taken four drugs (Prezista, Olysio, Jyseleca and Rekambys) to market. PW: Through our exclusive access to one of the world’s largest fibrosis tissue biobanks, we have correlated disease progression to gene expression data, enabling us to discover novel targets on the pathway that drives the advanced stages of fibrotic disease.

article thumbnail

Synthetic biology tools advancing and accelerating drug discovery efforts

Drug Discovery World

To accelerate drug development timelines, biotechs and pharma companies may choose to outsource some or all parts of antibody discovery and optimisation to DNA synthesis technology partners equipped with the tools and techniques to get reliable results faster. This approach has been around for a while.

DNA 98